Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

ClinicalTrials.gov ID: NCT00594165

Public ClinicalTrials.gov record NCT00594165. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 11:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.

Study identification

NCT ID
NCT00594165
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Pharma
Industry
Enrollment
217 participants

Conditions and interventions

Interventions

  • Rotigotine Drug

Drug

Eligibility (public fields only)

Age range
31 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2002
Primary completion
Oct 31, 2008
Completion
Oct 31, 2008
Last update posted
Oct 1, 2014

2002 – 2008

United States locations

U.S. sites
37
U.S. states
22
U.S. cities
37
Facility City State ZIP Site status
Not listed Peoria Arizona
Not listed Phoenix Arizona
Not listed Tucson Arizona
Not listed Fountain Valley California
Not listed Fresno California
Not listed Los Angeles California
Not listed Englewood Colorado
Not listed Danbury Connecticut
Not listed New Haven Connecticut
Not listed Miami Florida
Not listed Pompano Beach Florida
Not listed Sunrise Florida
Not listed Atlanta Georgia
Not listed Chicago Illinois
Not listed Fort Wayne Indiana
Not listed New Orleans Louisiana
Not listed Boston Massachusetts
Not listed Southfield Michigan
Not listed Minneapolis Minnesota
Not listed St Louis Missouri
Not listed Henderson Nevada
Not listed New Brunswick New Jersey
Not listed Albany New York
Not listed Louisville New York
Not listed New York New York
Not listed Asheville North Carolina
Not listed Durham North Carolina
Not listed Cleveland Ohio
Not listed Columbus Ohio
Not listed Toledo Ohio
Not listed Upland Pennsylvania
Not listed Dallas Texas
Not listed Houston Texas
Not listed San Antonio Texas
Not listed Richmond Virginia
Not listed Roanoke Virginia
Not listed Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00594165, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 1, 2014 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00594165 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →